88 related articles for article (PubMed ID: 23890383)
1. Discovery of survivin inhibitors and beyond: FL118 as a proof of concept.
Li F
Int Rev Cell Mol Biol; 2013; 305():217-52. PubMed ID: 23890383
[TBL] [Abstract][Full Text] [Related]
2. A novel small molecule FL118 that selectively inhibits survivin, Mcl-1, XIAP and cIAP2 in a p53-independent manner, shows superior antitumor activity.
Ling X; Cao S; Cheng Q; Keefe JT; Rustum YM; Li F
PLoS One; 2012; 7(9):e45571. PubMed ID: 23029106
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of FL118, a survivin, Mcl-1, XIAP, and cIAP2 selective inhibitor, is highly dependent on its primary structure and steric configuration.
Zhao J; Ling X; Cao S; Liu X; Wan S; Jiang T; Li F
Mol Pharm; 2014 Feb; 11(2):457-67. PubMed ID: 24329001
[TBL] [Abstract][Full Text] [Related]
4. An ABCG2 non-substrate anticancer agent FL118 targets drug-resistant cancer stem-like cells and overcomes treatment resistance of human pancreatic cancer.
Ling X; Wu W; Fan C; Xu C; Liao J; Rich LJ; Huang RY; Repasky EA; Wang X; Li F
J Exp Clin Cancer Res; 2018 Oct; 37(1):240. PubMed ID: 30285798
[TBL] [Abstract][Full Text] [Related]
5. Design, Synthesis, and In Vitro/In Vivo Anti-Cancer Activities of Novel (20
Dai X; Wu G; Zhang Y; Zhang X; Yin R; Qi X; Li J; Jiang T
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33187360
[TBL] [Abstract][Full Text] [Related]
6. Anticancer drug FL118 is more than a survivin inhibitor: where is the Achilles' heel of cancer?
Li F
Am J Cancer Res; 2014; 4(3):304-11. PubMed ID: 24959385
[TBL] [Abstract][Full Text] [Related]
7. In vitro evaluation of FL118 and 9-Q20 cytotoxicity and cellular uptake in 2D and 3D different cell models.
Weng Q; Zhou L; Xia L; Zheng Y; Zhang X; Li F; Li Q
Cancer Chemother Pharmacol; 2019 Sep; 84(3):527-537. PubMed ID: 31030236
[TBL] [Abstract][Full Text] [Related]
8. High-throughput screening for Survivin and Borealin interaction inhibitors in hepatocellular carcinoma.
Yue L; Li L; Li D; Yang Z; Han S; Chen M; Lan S; Xu X; Hui L
Biochem Biophys Res Commun; 2017 Mar; 484(3):642-647. PubMed ID: 28153734
[TBL] [Abstract][Full Text] [Related]
9. Piperine derivatives as potential inhibitors of Survivin: An in silico molecular docking.
Sattarinezhad E; Bordbar AK; Fani N
Comput Biol Med; 2015 Aug; 63():219-27. PubMed ID: 26093789
[TBL] [Abstract][Full Text] [Related]
10. Treat cancers by targeting survivin: just a dream or future reality?
Coumar MS; Tsai FY; Kanwar JR; Sarvagalla S; Cheung CH
Cancer Treat Rev; 2013 Nov; 39(7):802-11. PubMed ID: 23453862
[TBL] [Abstract][Full Text] [Related]
11. Small Molecule Inhibitors Targeting the "Undruggable" Survivin: The Past, Present, and Future from a Medicinal Chemist's Perspective.
Cui Q; Huang C; Liu JY; Zhang JT
J Med Chem; 2023 Dec; 66(24):16515-16545. PubMed ID: 38092421
[TBL] [Abstract][Full Text] [Related]
12. Targeting survivin in cancer: the cell-signalling perspective.
Kanwar JR; Kamalapuram SK; Kanwar RK
Drug Discov Today; 2011 Jun; 16(11-12):485-94. PubMed ID: 21511051
[TBL] [Abstract][Full Text] [Related]
13. Preclinical evidence for an effective therapeutic activity of FL118, a novel survivin inhibitor, in patients with relapsed/refractory multiple myeloma.
Holthof LC; van der Horst HJ; van Hal-van Veen SE; Ruiter RWJ; Li F; Buijze M; Andersen MN; Yuan H; de Bruijn J; van de Donk NWCJ; Lokhorst HM; Zweegman S; Groen RWJ; Mutis T
Haematologica; 2020; 105(2):e80-e83. PubMed ID: 31123033
[No Abstract] [Full Text] [Related]
14. Cancer therapeutics using survivin BIRC5 as a target: what can we do after over two decades of study?
Li F; Aljahdali I; Ling X
J Exp Clin Cancer Res; 2019 Aug; 38(1):368. PubMed ID: 31439015
[TBL] [Abstract][Full Text] [Related]
15. Survivin expression and targeting in breast cancer.
Jha K; Shukla M; Pandey M
Surg Oncol; 2012 Jun; 21(2):125-31. PubMed ID: 21334875
[TBL] [Abstract][Full Text] [Related]
16. Targeting survivin for therapeutic discovery: past, present, and future promises.
Peery RC; Liu JY; Zhang JT
Drug Discov Today; 2017 Oct; 22(10):1466-1477. PubMed ID: 28577912
[TBL] [Abstract][Full Text] [Related]
17. [Advances in study of Survivin inhibitors].
Meng YQ; Liu LW; Liu DY; Song YL
Yao Xue Xue Bao; 2016 Mar; 51(3):347-55. PubMed ID: 29858891
[TBL] [Abstract][Full Text] [Related]
18. Clinical aspects for survivin: a crucial molecule for targeting drug-resistant cancers.
Singh N; Krishnakumar S; Kanwar RK; Cheung CH; Kanwar JR
Drug Discov Today; 2015 May; 20(5):578-87. PubMed ID: 25433305
[TBL] [Abstract][Full Text] [Related]
19. Survivin in solid tumors: rationale for development of inhibitors.
Church DN; Talbot DC
Curr Oncol Rep; 2012 Apr; 14(2):120-8. PubMed ID: 22234703
[TBL] [Abstract][Full Text] [Related]
20. Inhibitor of apoptosis proteins: fascinating biology leads to attractive tumor therapeutic targets.
Varfolomeev E; Vucic D
Future Oncol; 2011 May; 7(5):633-48. PubMed ID: 21568679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
